⁍ Sales fell to $12.13 billion from $12.68 billion a year ago.
– Pfizer reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic. Sales fell to $12.13 billion from $12.68 billion a year ago.
Source: https://www.reuters.com/article/pfizer-results/pfizer-third-quarter-sales-fall-43-on-pain-drug-weakness-idUSL4N2HI2LU